Princess Margaret Cancer Center, Toronto, ON, Canada
Karen W. L. Yee , Michael Savona , Morten Sorensen , Peter Brown , William G. Blum , Daniel J. DeAngelo , Martin Gutierrez , Ramiro Garzon , Andre C. Schuh , Nashat Y. Gabrail , Martha Wadleigh , Jeffrey E. Lancet , Bijal D. Shah , Jesus G. Berdeja , Nina D. Wagner-Johnston , Ian Flinn , Tami Rashal , Michael Kauffman , Sharon Shacham , Richard M. Stone
Background: KPT-330 (Selinexor) is a slowly reversible XPO1 inhibitor that forces the nuclear retention and activation of >10 tumor suppressor proteins (TSP) including NPM1c, reduces cMYC and BCLx, and induces AML cell death while sparing normal hematopoietic cells. Methods: Oral KPT-330 was given at 8-10 doses per 28-day cycle. Elevation in leukocyte XPO1 mRNA following XPO1 inhibition was a pharmacodynamic (PDn) marker for KPT-330 activity. Pharmacokinetic (PK) analyses were performed. Appetite stimulants and anti-emetics were given as part of supportive care. Results: 48 pts (24 M / 24 F; median age 68 yrs; ECOG PS 0/1: 11/37; pts were heavily pretreated with median 3 prior regimens (range of 1-7). Pts received KPT-330 across 5 dose levels (16.8 - 55 mg/m2). There have been no DLTs. Cycle 1 grade 3/4 non-DLT adverse events (AEs) in >1 pt included: fatigue (8%), thrombocytopenia (8%), neutropenia (8%), and nausea (4%). The most common Cycle 1 grade 1/2 AEs were diarrhea (35%), anorexia (33%), nausea (29%), and fatigue (25%). Prolonged administration (>4 months) of KPT-330 was feasible and there were no drug-associated deaths. PK and PDn analyses showed dose-dependent increases in Cmax / AUC0-inf (T1/2 ~6 hrs) and increases in XPO1 mRNA. Higher doses of KPT-330 were associated with greater reductions in blast counts, which were also observed across different AML subtypes. 16 pts did not complete cycle 1 and were therefore not evaluable for response. Responses in 32 evaluable pts were: complete response (CR) with full hematological recovery: 4 pts (12%), marrow CR (CRm): 1 pt (3%), CR without hematological recovery: 1 pt (3%), duration of CR/CRi/CRm 6-13 weeks; Morphological leukemia free state: 1 pt (3%), Partial Response (PR) 2 pts (6%). Twelve (37%) of the remaining pts have experienced stable disease for > 30 days, and 11 (34%) have had progressive disease. Conclusions: KPT-330 treatment can be given over months and induce remissions in pts with heavily pretreated AML. A randomized study of KPT-330 vs available agents in chemotherapy-ineligible relapsed AML is being initiated. Clinical trial information: NCT01607892.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2014 ASCO Annual Meeting
First Author: Martin Gutierrez
2022 ASCO Annual Meeting
First Author: Haris Ali
2013 ASCO Annual Meeting
First Author: Albiruni R A Razak
2014 ASCO Annual Meeting
First Author: John Martignetti